Calcimedica reports third quarter 2023 financial results and provides clinical & corporate updates

Continued expansion of phase 1/2 crspa study of auxora™ in asparaginase-induced pancreatic toxicity (aipt); data from initial cohort to be presented at 65th annual  american society of hematology (ash) meeting & exposition international expansion of phase 2b carpo trial in acute pancreatitis (ap) patients with accompanying systemic inflammatory response syndrome (sirs) continues; topline data expected in the first half of 2024 la jolla, calif. , nov. 9, 2023 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended september 30, 2023.
CALC Ratings Summary
CALC Quant Ranking